CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 22 No. 5
Pages: 1  2  
Next
Clinical Quandaries 

Management of a Patient With Stage IIIA (N2) NSCLC

By Kathryn Carlson, MSN, APRN-BC, WHNP-BC
Department of Hematology and Medical Oncology

B. Zach Fowler, MD
Department of Radiation Oncology

Daniel L. Miller, MD
Division of Thoracic Surgery

Anthony Gal, MD
Department of Pathology

Suresh Ramalingam, MD
Department of Hematology
and Medical Oncology
Emory University
School of Medicine
Emory Winship Cancer Institute
Atlanta, Georgia

| April 30, 2008
The appropriate treatment of patients with stage IIIA (N2) non–small-cell lung cancer (NSCLC) is unclear. With this case report and review, we address the history, assessment, and management of a 67-year-old patient with this diagnosis, and then discuss the challenges in managing N2 disease, as well as the roles of systemic therapy, surgery, and postoperative radiation therapy.

The management of patients with stage IIIA (N2) non–small-cell lung cancer (NSCLC) is controversial. In this installment of Clinical Quandaries, we present the case of a man with this diagnosis and review the variety of available treatment options.

Case Report

A 67-year-old male was found to have a mass in the left upper lobe of the lung on a routine chest radiograph that was done as part of preoperative work-up for an elective inguinal hernia repair. Following this, a computed tomography (CT) scan of the chest revealed a 2.0 x 1.4 cm soft-tissue density in the lingula (Figure 1A). An enlarged lymph node (1.4 x 1.1 cm) was also noted in the aortopulmonary (AP) window. A small hypodense lesion was noted in the liver. No other abnormalities were noted on the chest CT scan. The patient subsequently underwent a positron-emission tomography (PET) scan. The lingular soft-tissue density and the AP lymph node were both metabolically active with standardized uptake value (SUV) of 5.0 and 4.8, respectively (Figure 1B). The lesion in the liver was not FDG-avid. There was no evidence of extrathoracic disease.

The patient underwent a CT-guided fine-needle aspiration of the left lingular lesion. The biopsy was consistent with poorly differentiated adenocarcinoma. Immunohistochemical stains were positive for cytokeratin 7 and thyroid transcription factor-1, and negative for cytokeratin 20. These findings were consistent with identifying the lung as the primary site of the cancer. In order to evaluate the liver lesion further, a magnetic resonance imaging (MRI) scan of the liver was obtained. The findings suggested the liver lesion to be a benign cyst.

The patient's past medical history was pertinent for hypertension, peptic ulcer disease, basal cell carcinoma of the skin, and benign prostatic hyperplasia. He was on treatment with atenolol(Drug information on atenolol) and famotidine(Drug information on famotidine) for his medical illnesses. The patient did not have known allergy to any medications. He quit smoking cigarettes in 1975 and had a 20 pack-year history prior to that. The patient consumed alcohol(Drug information on alcohol) on a social basis (two drinks per week). He had no history of exposure to asbestos.

His physical exam was pertinent for a slightly elevated blood pressure of 148/90 mm Hg, reducible right inguinal hernia, and a healed surgical scar in the right upper quadrant of the abdomen from a prior cholecystectomy. His respiratory exam was normal. The patient had an excellent functional status. His performance status on the Eastern Cooperative Oncology Group (ECOG) scale was 0.

Based on the above information, his lung cancer was diagnosed as clinical stage IIIA (T1, N2, Mx). Initial laboratory evaluation revealed normal bone marrow, hepatic, and renal function. Pulmonary function tests revealed a forced expiratory volume in 1 second (FEV1) of 2.6 liters (80% of predicted value).

Treatment

Management of this patient was discussed at a multidisciplinary conference that was attended by thoracic surgeons, medical oncologists, radiation oncologists, and pulmonologists. The patient underwent an outpatient left video-assisted thoracic surgery (VATS) to sample the enlarged AP window lymph node. The biopsy was positive for adenocarcinoma. Based on this, it was decided to administer neoadjuvant chemotherapy. The patient was treated with the combination of cisplatin(Drug information on cisplatin) (75 mg/m2) and docetaxel(Drug information on docetaxel) (Taxotere, 75 mg/m2) every 3 weeks for a total of three cycles. He tolerated the treatment well overall. The adverse events associated with chemotherapy included grade 2 fatigue and anemia, grade 3 neutropenia, and grade 1 nausea.

Following completion of the chemotherapy, the patient underwent a repeat PET/CT scan. The new imaging studies showed a slight reduction in size of the lingular lesion and a near-complete resolution of the AP window lymph node (Figure 2). The latter was non–FDG-avid on the follow-up scan, whereas the primary lesion continued to be PET-positive with a lower SUV of 2.8. His performance status remained excellent.

Figure 1

Subsequently, the patient underwent a left thoracotomy and upper lobectomy with complete mediastinal lymph node dissection. The surgical pathologic evaluation revealed a 2.2 x 1.7 cm adenocarcinoma of the lung along with involvement of the visceral pleura (T2) (Figure 3A). The bronchial and vascular margins were negative. A total of 28 lymph nodes were removed from N1 and N2 stations; only three lymph nodes were positive for adenocarcinoma in the AP window and subcarinal region (Figure 3B). Final pathologic stage was IIIA (T2, N2, M0) adenocarcinoma of the left upper lobe.

The patient recovered from surgery and presented for discussion of further treatment options 4 weeks postoperatively. It was decided that radiation therapy would be administered. The role of chemotherapy in this setting was discussed with the patient. The absence of data to recommend additional chemotherapy was explained, and the patient made an informed decision not to receive any further chemotherapy. He tolerated radiotherapy well and received a total of 50.4 Gy (1 fraction/d x 5.5 weeks).

The patient has been on routine follow-up care, with no evidence of disease recurrence approximately 1 year later.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





Address all correspondence to: Suresh S. Ramalingam, MD
Acting Associate Professor
Chief of Thoracic Medical Oncology
Emory University School of Medicine
Emory Winship Cancer Institute
1365 Clifton Rd, Rm C-5090
Atlanta, GA 30322
e-mail: suresh.ramalingam@emory.edu


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy